Virtual meeting
AABB 2021
Quotient is proud to continue supporting the AABB community as a 2021 Corporate Partner. In this role, we support the organization’s mission of, “improving lives by making transfusion medicine and biotherapies safe, available, and effective worldwide. “
AABB Corporate Partner

The MosaiQ™ System has the potential to be the world’s first fully automated consolidated testing platform.

Powered by a trio of innovations and developed by the immunohematology experts at Quotient, the MosaiQ System is designed to provide labs with a multimodal, multiplexing walkaway testing.


Microscopic Printing

This novel idea was inspired by microarray technology and combines biochemistry principles with microchip design from the semiconductor industry. The innovative design saves biological and testing resources, as each microarray can be printed with up to 132 biologic spots enabling multiplex results.


The instrument is designed to hold up to four different types of MosaiQ Magazines at once, which would allow for one sample to be tested across different modalities. Well-characterized blood typing and serological and molecular disease screening will be possible with a single tube of blood.

Photometric Immunoassay

This unique reaction uses the direct method for antigen detection and the indirect method for antibody detection. A precise wavelength of light illuminates the spots on the microarray and the high-resolution camera detects results via dark field imaging. An automated algorithm then displays easily readable results on the graphical user interface.

MosaiQ System
Interested in going behind the scenes?
Quotient is offering a limited series of VIP user experiences. Register today for the opportunity to join us.

Alba by Quotient™
Quality blood bank reagents backed by technical expertise.

Laboratories around the world run efficiently thanks to Alba by Quotient products available directly or through OEM partners. Learn more about the availability of Alba products in your area and request samples for evaluation today.


Antibody Panel Highlights

Resolve more with 16+4. Alba by Quotient red cell panels work in tandem to resolve the antibodies that you see most often. Learn more about what makes our panels so powerful.


Monoclonal Anti-Fyb

Tired of waiting? Alba's Anti-Fyb is immediate spin and provides a robust reaction with just one drop and no AHG step is required. Check out our other immediate spin products like Jka, Jkand P1


US Product List

Licensed products, state-of-the-art manufacturing, and excellent technical support ensure that our customers receive high-quality reagents and reliable results day in and day out.

Alba by Quotient
We make it easy to evaluate our products.
For more information, fill out the details and we’ll be in touch.

Recent Scientific Publications

These presentations are for education purposes only. Copies of posters and publications are for personal use only and may not be reproduced without permission from the author. Contact for more information.

Evaluation of the Quotient® MosaiQTM COVID-19 Antibody Microarray for the detection of IgG and IgM antibodies to SARS-CoV-2 virus in humans

The MosaiQ® COVID-19 Antibody test fulfills the minimal requirements for serological testing according to the French regulation.


MosaiQ COVID-19
MosaiQ Instrument
Evaluation of the MosaiQTM Serological Disease Screening Microarray System for Detection of Antibodies to Human Cytomegalovirus and Treponema pallidum

The study demonstrated that the MosaiQ platform is suitable for screening of blood donations for antibodies to CMV and T. pall. The platform demonstrated suitable sensitivity and specificity to be considered fit for its intended purpose, and has subsequently been submitted for consideration by regulatory bodies.


Evaluation of the performance of the quotient MosaiQTM COVID-19 professional use microarray assay for the detection of antibodies to SARS CoV-2 in a clinical setting

Antibody testing can provide valuable information to guide health- care providers and inform the management of patients. In an ELISA based method, SARS-CoV-2-specific antibodies were detectable in approximately 40% of COVID-19 patients at seven days after the onset of symptoms, and seroconversion rates exceed >90% at the comparatively early time of day 14.


MosaiQ COVID-19